vestimИзвестия Национальной академии наук Беларуси. Серия медицинских наукProceedings of the National Academy of Sciences of Belarus, Medical series1814-60232524-2350The Republican Unitary Enterprise Publishing House "Belaruskaya Navuka"10.29235/1814-6023-2024-21-1-33-42vestim-951Research ArticleКЛИНИЧЕСКАЯ И ЭКСПЕРИМЕНТАЛЬНАЯ МЕДИЦИНАCLINICAL AND EXPERIMENTAL MEDICINEРаспределение генотипов гена SLC2A9 и его взаимосвязь с уровнем мочевой кислоты у пациентов с артериальной гипертензией и фибрилляцией предсердийDistribution of the SLC2A9 genotype and its association with the uric acid level in patients with arterial hypertension and atrial fibrillationhttps://orcid.org/0000-0001-7117-2182БорисенкоТ. Л.BarysenkaT. L.

Борисенко Татьяна Леоновна – ассистент

ул. Горького, 80, 230015, г. Гродно

Tatyana L. Barysenka – Assistant

80, Gorky Str., 230015, Grodno

t.kepourko@gmail.comhttps://orcid.org/0000-0002-1706-1243СнежицкийВ. А.SnezhitskiyV. A.

Снежицкий Виктор Александрович – член-корреспондент, д-р мед. наук, профессор

ул. Горького, 80, 230015, г. Гродно

Viktor A. Snezhitskiy – Corresponding Member, D. Sc. (Med.), Professor

80, Gorky Str., 230015, Grodno

vsnezh@grsmu.byhttps://orcid.org/0000-0001-9939-8749КурбатМ. Н.KurbatM. N.

Курбат Михаил Николаевич – канд. биол. наук, до­цент, вед. науч. сотрудник

ул. Горького, 80, 230015, г. Гродно

Mikhail N. Kurbat – Ph. D. (Med.), Associate Professor, Leading Researcher

80, Gorky Str., 230015, Grodno

vwmisha@mail.ruhttps://orcid.org/0000-0001-7732-7587ГорчаковаО. В.GorchakovaO. V.

Горчакова Ольга Владимировна – ст. науч. сотруд­ник

ул. Горького, 80, 230015, г. Гродно

Olga V. Gorchakova – Senior Researcher

80, Gorky Str., 230015, Grodno

daniil_go@inbox.ruhttps://orcid.org/0000-0002-1862-4300КопыцкийА. В.KopytskyA. V.

Копыцкий Андрей Витальевич – ст. преподаватель

ул. Горького, 80, 230015, г. Гродно

Andrey V. Kopytsky – Senior Lecturer

80, Gorky Str., 230015, Grodno

Andrey_cop@mail.ruГродненский государственный медицинский университетGrodno State Medical University2024040320242113342Copyright © Борисенко Т.Л., Снежицкий В.А., Курбат М.Н., Горчакова О.В., Копыцкий А.В., 20242024Борисенко Т.Л., Снежицкий В.А., Курбат М.Н., Горчакова О.В., Копыцкий А.В.Barysenka T.L., Snezhitskiy V.A., Kurbat M.N., Gorchakova O.V., Kopytsky A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestimed.belnauka.by/jour/article/view/951

Бессимптомная гиперурикемия (ГУ) широко распространена в популяции и является одним из ос­новных факторов риска сердечно-сосудистых заболеваний. Данные многочисленных исследований подтверждают взаимосвязь между повышением уровня мочевой кислоты (МК) и риском развития артериальной гипертензии (АГ) и/или фибрилляции предсердий (ФП). Одной из причин повышения уровня МК и значимым фактором риска возник­новения ГУ является наличие полиморфизма гена SLC2A9 – высокоспецифического транспортера уратов в клетках проксимальных почечных канальцев, кодирующего белок GLUT9.

Цель исследования – изучить частоту встречаемости генотипов и аллелей полиморфного варианта rs734553 гена SLC2A9 и его взаимосвязь с уровнем МК у пациентов с АГ и ФП, а также у здоровых лиц.

Обследован 141 пациент, из них 50 – здоровые пациенты (1-я группа), 68 – с АГ и ФП (2-я группа), 23 – с АГ (3-я группа).

В общей выборке пациентов частоты генотипов полиморфизма rs734553 гена SLC2A9 были следующие: АА – 46,1 % (n = 65), АС – 36,2 % (n = 51), СС – 17,7 % (n = 25). Согласно результатам генотипирования пациентов, в 1-й группе генотип АА составил 64 % (n = 32), АС – 22 % (n = 11), СС – 14 % (n = 7); во 2-й группе ‒ 32,4 % (n = 22), 48,5 % (n = 33) и 19,1 % (n = 13); в 3-й группе – 47,8 % (n = 11), 30,4 % (n = 7) и 21,7 % (n = 5) соответственно. У пациентов с генотипом СС (420 [413; 424] мкмоль/л) и генотипом АС (330 [284; 412] мкмоль/л) величина урикемии была выше, чем у лиц с генотипом АА (310 [281; 341] мкмоль/л) (p = 0,003). ГУ с генотипом АА во 2-й группе была диагностиро­вана у 2 (2,9 %) пациентов, с генотипом АС – у 12 (17,6 %), с генотипом СС – у 10 (14,7 %); в 3-й группе ‒ у 1 (4,3 %), 1 (4,3 %) и 3 (13 %) соответственно. Один пациент (2 %) с ГУ из 1-й группы имел генотип СС.

Установлено распределение частот генотипов и аллелей полиморфного варианта rs734553 гена SLC2A9 и его взаимосвязь с уровнем МК у пациентов с АГ и ФП, а также у здоровых лиц. У пациентов с АГ и ФП генотип АС встречал­ся в 3 раза чаще, а генотип СС в 2 раза чаще, чем у здоровых пациентов. ГУ встречался достоверно чаще ( р = 0,003) в группе пациентов с АГ и ФП и генотипом СС, а также у пациентов с генотипом СС.

Asymptomatic hyperuricemia (HU) is widespread in the population and is one of the main risk factors for cardiovascular diseases. Evidence of numerous studies supports the association between increased uric acid (UA) levels and the risk of arterial hypertension (HTN) and/or atrial fibrillation (AF). One of the causes for an increase in UA levels and a significant risk factor for HU is the polymorphism of the SLC2A9 gene, a highly specific urate transporter in proximal renal tubule cells, encoding the GLUT9 protein.

The aim of the study is to investigate the frequency of genotypes and alleles of the SLC2A9 gene rs734553 polymorphic variant and its association with the UA level in patients with HTN and AF, as well as in healthy individuals. 141 patients, including 50 healthy patients (group 1), 68 – with HTN and AF (group 2), 23 – with HTN (group 3) were examined.

In the overall group of patients, the frequencies of the SLC2A9 gene rs734553 polymorphism were as follows: AA – 46.1 % (n = 65), AC – 36.2 % (n = 51), CC – 17.7 % (n = 25). According to the genotyping results of patients, in group 1 the AA genotype was 64 % (n = 32), AC – 22 % (n = 11), CC – 14 % (n = 7); in group 2 – 32.4 % (n = 22), 48.5 % (n = 33) and 19.1 % (n = 13); in group 3 47.8 % (n = 11), 30.4 % (n = 7) and 21.7 % (n = 5), respectively. The CC genotype patients (420 [413; 424] μmol/l) and the AC genotype patients (330 [284; 412] μmol/l) had higher uricemia values than those with the AA genotype (310 [281; 341] μmol/l) ( p = 0,003). HU with the AA genotype in group 2 was diagnosed in 2 (2.9 %) patients, with the AC genotype in 12 (17.6 %), and with the CC genotype in 10 (14.7 %) patients; in group 3 – 1 (4.3 %), 1 (4.3 %) and 3 (13 %), respectively. One patient (2 %) with HU in group 1 had the CC genotype.

The distribution of genotype and allele frequencies of the SLC2A9 gene rs734553 polymorphic variant and its association with the UA level in patients with HTN and AF, as well as in healthy individuals were established. In patients with HTN and AF, the AC genotype occurred 3 times more often and the CC genotype occurred 2 times more often than in healthy patients. HU occurred significantly more often ( р = 0.003) in the group of patients with HTN and AF and the CC genotype, as well as in patients with the CC genotype.

артериальная гипертензияфибрилляция предсердиймочевая кислотагиперурикемияпо­лиморфизм гена SLC2A9arterial hypertensionatrial fibrillationuric acidhyperuricemiaSLC2A9 gene polymorphismReferencesГенетические маркеры фибрилляции предсердий на фоне гипертонической болезни в сочетании с экстракардиальными заболеваниями / Л. Хидирова [и др.] // Патология кровообращения и кардиохирургия. – 2019. – Т. 23, № 1. – С. 83–85.Khidirova L., Yakhontov D., Zenin S., Maksimov V. Genetic markers of atrial fibrillation in patients with hypertension in combination with non-cardiac diseases. Patologiya krovoobrashcheniya i kardiokhirurgiya [Circulation pathology and cardiac surgery], 2019, vol. 23, no. 1, pp. 83–85 (in Russian).European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardiaca y Electrofisiologia (SOLAECE) / D. G. Katritsis [et al.] // Eur. Heart J. – 2018. – Vol. 39, N 16. – P. 1442–1445. https://doi.org/10.1093/eurheartj/ehw455Katritsis D. G., Boriani G., Cosio F. G., Hindricks G., Jais P., Josephson M. E. [et al.]. European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardiaca y Electrofisiologia (SOLAECE). European Heart Journal, 2018, vol. 39, no. 16, pp. 1442–1445. https://doi.org/10.1093/eurheartj/ehw455Serum uric acid and the risk of cardiovascular and renal disease / C. Borghi [et al.] // J. Hypertens. – 2015. – Vol. 33, N 9. – P. 1729–1741. https://doi.org/10.1097/HJH.0000000000000701Borghi C., Rosei E. A., Bardin T., Dawson J., Dominiczak A., Kielstein J. T., Manolis A. J., Perez-Ruiz F., Mancia G. Serum uric acid and the risk of cardiovascular and renal disease. Journal of Hypertension, 2015, vol. 33, no. 9, pp. 1729–1741. https://doi.org/10.1097/HJH.0000000000000701Кобалава, Ж. Д. Бессимптомная гиперурикемия и риск развития сердечно-сосудистых и почечных заболеваний / Ж. Д. Кобалава, Е. А. Троицкая // Кардиология. – 2020. – Т. 60, № 10. – С. 113–121.Kobalava Zh. D., Troitskaya E. A. Asymptomatic hyperuricemia and risk of cardiovascular and renal diseases. Kardiologiya [Cardiology], 2020, vol. 60, no. 10, pp. 113–121 (in Russian).2018 ESC/ESH Guidelines for the management of arterial hypertension / B. Williams [et al.] // Eur. Heart J. – 2018. – Vol. 39, N 33. – P. 3021–3104. https://doi.org/10.1093/eurheartj/ehy339Williams B., Mancia G., Spiering W., Agabiti Rosei E., Azizi M., Burnier M. [et al.]. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 2018, vol. 39, no. 33, pp. 3021–3104. https://doi.org/10.1093/eurheartj/ehy339Артериальная гипертензия у взрослых. Клинические рекомендации 2020 / Ж. Д. Кобалава [и др.] // Рос. кардиол. журн. – 2020. – Т. 25, № 3. – С. 149–218.Kobalava Zh. D., Konradi A. O., Nedogoda S. V., Shlyakhto E. V., Arutyunov G. P., Baranova E. I. [et al.]. Arterial hypertension in adults. Clinical guidelines 2020. Rossiiskii kardiologicheskii zhurnal [Russian journal of cardiology], 2020, vol. 25, no. 3, pp. 149–218 (in Russian).Роль полиморфизма SLC2A9, ABCG2 генов в возникновении гиперурикемии и подагры // А. А. Фадеева [и др.] // Georg. Med. News. – 2016. – Т. 252, № 3. – С. 79–83.Fadeeva A. A., Pristupa L. N., Pogorelova O. S., Kirichenko N. N., Dudchenko I. A. The role of SLC2A9, ABCG2 gene polymorphism in the occurrence of hyperuricemia and gout. Georgian Medical News, 2016, vol. 252, no. 3, pp. 79–83 (in Russian).The genetics of hyperuricaemia and gout / A. M. Reginato [et al.] // Nat. Rev. Rheumatol. – 2012. – Vol. 8, N 10. – P. 610–621. https://doi.org/10.1038/nrrheum.2012.144Reginato A. M., Mount D. B., Yang I., Choi H. K. The genetics of hyperuricaemia and gout. Nature Reviews Rheumatology, 2012, vol. 8, no. 10, pp. 610–621. https://doi.org/10.1038/nrrheum.2012.144Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia / C. Wallace [et al.] // Am. J. Hum. Genet. – 2008. – Vol. 82, N 1. – P. 139–149. https://doi.org/10.1016/j.ajhg.2007.11.001Wallace C., Newhouse S. J., Braund P., Zhang F., Tobin M., Falchi M. [et al.]. Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. American Journal of Human Genetics, 2008, vol. 82, no. 1, pp. 139–149. https://doi.org/10.1016/j.ajhg.2007.11.001Effects of SLC2A9 variants on uric acid levels in a Korean population / J. W. Sull [et al.] // Rheumatol. Int. – 2013. – Vol. 33, N 1. – P. 19–23. https://doi.org/10.1007/s00296-011-2303-2Sull J. W., Park E. J., Lee M., Jee S. H. Effects of SLC2A9 variants on uric acid levels in a Korean population. Rheumatology International, 2013, vol. 33, no. 1, pp. 19–23. https://doi.org/10.1007/s00296-011-2303-2Barysenka, T. L. The role of hyperuricemia in the development of atrial fibrillation / T. L. Barysenka, V. A. Snezhitskiy // Cardiac Arrhythmias. – 2021. – Т. 1, № 1. – C. 7–16.Barysenka T. L., Snezhitskiy V. A. The role of hyperuricemia in the development of atrial fibrillation. Cardiac Arrhythmias, 2021, vol. 1, no. 1, pp. 7–16.The prevalence of hyperuricemia in China: a meta-analysis / B. Liu [et al.] // BMC Public Health. – 2011. – N 11. – Art. 832. https://doi.org/10.1186/1471-2458-11-832Liu B., Wang T., Zhao H. N., Yue W. W., Yu H. P., Liu C. X., Yin J, Jia R. Y., Nie H. W. The prevalence of hyperuricemia in China: a meta-analysis. BMC Public Health, 2011, vol. 11, art. 832. https://doi.org/10.1186/1471-2458-11-832Жернакова, Ю. В. Гиперурикемия как фактор риска сердечно-сосудистых заболеваний – что нового? / Ю. В. Жернакова // Мед. алфавит. – 2020. – № 13. – С. 5–11.Zhernakova Yu. V. Hyperuricemia as a risk factor for cardiovascular disease – what’s new? Meditsinskii alfavit [Medical alphabet], 2020, no. 13, pp. 5–11 (in Russian).Lin, K. C. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study / K. C. Lin, H. Y. Lin, P. Chou // J. Rheumatol. – 2000. – Vol. 27, N 6. – P. 1501–1505.Lin K. C., Lin H. Y., Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. Journal of Rheumatology, 2000, vol. 27, no. 6, pp. 1501–1505.Hyperuricemia and incident hypertension: a systematic review and meta-analysis / P. C. Grayson [et al.] // Arthritis Care Res. (Hoboken). – 2011. – Vol. 63, N 1. – P. 102–110. https://doi.org/10.1002/acr.20344Grayson P. C., Kim S. Y., LaValley M., Choi H. K. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care and Research (Hoboken), 2011, vol. 63, no. 1, pp. 102–110. https://doi.org/10.1002/acr.20344Prognostic value of serum uric acid: new-onset in and out-of-office hypertension and long-term mortality / M. Bombelli [et al.] // J. Hypertens. – 2014. – Vol. 32, N 6. – P. 1237–1244. https://doi.org/10.1097/HJH.0000000000000161Bombelli M., Ronchi I., Volpe M, Facchetti R., Carugo S., Dell’oro R., Cuspidi C., Grassi G., Mancia G. Prognostic value of serum uric acid: new-onset in and out-of-office hypertension and long-term mortality. Journal of Hypertension, 2014, vol. 32, no. 6, pp. 1237–1244. https://doi.org/10.1097/HJH.0000000000000161Asymptomatic hyperuricemia and coronary artery disease in elderly patients without comorbidities / J. Wu [et al.] // Oncotarget. – 2017. – Vol. 8, N 46. – P. 80688–80699. https://doi.org/10.18632/oncotarget.21079Wu J., Lei G., Wang X., Tang Y., Cheng H., Jian G., Wu X., Wang N. Asymptomatic hyperuricemia and coronary artery disease in elderly patients without comorbidities. Oncotarget, 2017, vol. 8, no. 46, pp. 80688–80699. https://doi.org/10.18632/oncotarget.21079Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study / P. Verdecchia [et al.] // Hypertension. – 2000. – Vol. 36, N 6. – P. 1072–1078. https://doi.org/10.1161/01.hyp.36.6.1072Verdecchia P., Schillaci G., Reboldi G., Santeusanio F., Porcellati C., Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Journal of Hypertension, 2000, vol. 36, no. 6, pp. 1072–1078. https://doi.org/10.1161/01.hyp.36.6.1072Prognostic value of hyperuricemia in patients with acute coronary syndrome: A meta-analysis / C. He [et al.] // Eur. J. Clin. Invest. – 2019. – Vol. 49, N 4. – P. e13074. https://doi.org/10.1111/eci.13074He C., Lin P., Liu W., Fang K. Prognostic value of hyperuricemia in patients with acute coronary syndrome: a metaanalysis. European Journal of Clinical Investigation, 2019, vol. 49, no. 4, p. e13074. https://doi.org/10.1111/eci.13074The relationship between serum uric acid and ejection fraction of the left ventricle / I. Vlad-Sabin [et al.] // J. Clin. Med. – 2021. – Vol. 10, N 17. – Art. 4026. https://doi.org/10.3390/jcm10174026Vlad-Sabin I., Roxana B., Adina-Flavia C. M., Paul C., Melania A., Daniel G., Llie R. C., Romulus T., Daniel L. The relationship between serum uric acid and ejection fraction of the left ventricle. Journal of Clinical Medicine, 2021, vol. 10, no. 17, art. 4026. https://doi.org/10.3390/jcm10174026The prognostic value of serum uric acid in hospitalized patients with acute cerebral infarction / B. Liu [et al.] // Dis. Markers. – 2021. – Vol. 2021. – Art. 6103961. https://doi.org/10.1155/2021/6103961Liu B., Pan Y., Cao L., Yang J. The prognostic value of serum uric acid in hospitalized patients with acute cerebral infarction. Disease Markers, 2021, vol. 2021, art. 6103961. https://doi.org/10.1155/2021/6103961The key role of uric acid in oxidative stress, inflammation, fibrosis, apoptosis, and immunity in the pathogenesis of atrial fibrillation / Y. Deng [et al.] // Front Cardiovasc. Med. – 2021. – Vol. 8. – Art. 641136. https://doi.org/10.3389/fcvm.2021.641136Deng Y., Liu F., Yang X., Xia Y. The key role of uric acid in oxidative stress, inflammation, fibrosis, apoptosis, and immunity in the pathogenesis of atrial fibrillation. Frontiers in Cardiovascular Medicine, 2021, vol. 8, art. 641136. https://doi. org/10.3389/fcvm.2021.641136 23. Mazurov V. I., Bashkinov R. A., Gaidukova I. Z., Fonturenko A. Yu. The effect of asymptomatic hyperuricemia on comorbidities and the possibility of its correction. Russkii meditsinskii zhurnal [Russian medical journal], 2021, no. 7, pp. 24–30 (in Russian). 24. Matsuo H., Yamamoto K., Nakaoka H., Nakayama A., Sakiyama M., Chiba T. [et al.]. Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes. Annals of the Rheumatic Diseases, 2016, vol. 75, no. 4, pp. 652–659. https://doi.org/10.1136/annrheumdis-2014-206191Мазуров, В. И. Влияние бессимптомной гиперурикемии на коморбидные заболевания и возможности ее коррекции / В. И. Мазуров // РМЖ. – 2021. – № 7. – С. 24–30.Vitart V., Rudan I., Hayward C., Gray N. K., Floyd J., Palmer C. N. A. [et al.]. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nature Genetics, 2008, vol. 40, no. 4, pp. 437– 442. https://doi.org/10.1038/ng.106Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes / H. Matsuo [et al.] // Ann. Rheum. Dis. – 2016. – Vol. 75, N 4. – P. 652–659. https://doi.org/10.1136/annrheumdis-2014-206191Yi X.-L., Li J., Meng D.-M., Liu Y.-J., Liu Y.-H., Ma H.-M., Yuan Yi, Xing S.-C. An intron variant of SLC2A9 increases the risk for type 2 diabetes mellitus complicated with hyperuricemia in Chinese male population. Iranian Journal of Public Health, 2018, vol. 47, no. 6, pp. 844–851.SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout / V. Vitart [et al.] // Nat. Genet. – 2008. – Vol. 40, N 4. – P. 437–442. https://doi.org/10.1038/ng.106Testa A., Mallamaci F., Spoto B., Pisano A., Sanguedolce M. C., Tripepi G., Leonardis D., Zoccali C. Association of a polymorphism in a gene encoding a urate transporter with CKD progression. Clinical Journal of the American Society of Nephrology, 2014, vol. 9, no. 6, pp. 1059–1065. https://doi.org/10.2215/CJN.11041013An intron variant of SLC2A9 increases the risk for type 2 diabetes mellitus complicated with hyperuricemia in Chinese male population / X.-L. Yi [et al.] // Iran J. Publ. Health. – 2018. – Vol. 47, N 6. – P. 844–851.Parsa A., Brown E., Weir M. R., Fink J. C., Shuldiner A. R., Mitchell B. D., McArdle P. F. Genotype-based changes in serum uric acid affect blood pressure. Kidney International, 2012, vol. 81, no. 5, pp. 502–507. https://doi.org/10.1038/ki.2011.414Association of a polymorphism in a gene encoding a urate transporter with CKD progression / A. Testa [et al.] // Clin. J. Am. Soc. Nephrol. – 2014. – Vol. 9, N 6. – P. 1059–1065. https://doi.org/10.2215/CJN.11041013Mallamaci F., Testa A., Leonardis D., Tripepi R., Pisano A., Spoto B., Sanguedolce M. C., Parlongo R. M., Tripepi G., Zoccali C. A polymorphism in the major gene regulating serum uric acid associates with clinic SBP and the white-coat effect in a family-based study. Journal of Hypertension, 2014, vol. 32, no. 8, pp. 1621–1628. https://doi.org/10.1097/HJH.0000000000000224Genotype-based changes in serum uric acid affect blood pressure / A. Parsa [et al.] // Kidney Int. – 2012. – Vol. 81, N 5. – P. 502–507. https://doi.org/10.1038/ki.2011.414Mallamaci F., Testa A., Leonardis D., Tripepi R., Pisano A., Spoto B., Sanguedolce M. C., Parlongo R. M., Tripepi G., Zoccali C. A. Genetic marker of uric acid level, carotid atherosclerosis, and arterial stiffness: A family-based study. American Journal of Kidney Diseases, 2015, vol. 65, no. 2, pp. 294–302. https://doi.org/10.1053/j.ajkd.2014.07.021A polymorphism in the major gene regulating serum uric acid associates with clinic SBP and the white-coat effect in a family-based study / F. Mallamaci [et al.] // J. Hypertens. – 2014. – Vol. 32, N 8. – P. 1621–1628. https://doi.org/10.1097/HJH.0000000000000224A polymorphism in the major gene regulating serum uric acid associates with clinic SBP and the white-coat effect in a family-based study / F. Mallamaci [et al.] // J. Hypertens. – 2014. – Vol. 32, N 8. – P. 1621–1628. https://doi.org/10.1097/HJH.0000000000000224A genetic marker of uric acid level, carotid atherosclerosis, and arterial stiffness: A family-based study / F. Mallamaci [et al.] // Am. J. Kidney Dis. – 2015. – Vol. 65, N 2. – P. 294–302. https://doi.org/10.1053/j.ajkd.2014.07.021A genetic marker of uric acid level, carotid atherosclerosis, and arterial stiffness: A family-based study / F. Mallamaci [et al.] // Am. J. Kidney Dis. – 2015. – Vol. 65, N 2. – P. 294–302. https://doi.org/10.1053/j.ajkd.2014.07.021

The authors declare that there are no conflicts of interest present.